Skip to main content
204 search results for:

Tocilizumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 11-10-2022 | Rheumatoid arthritis | News | Article

    Serum calprotectin could indicate inflammatory activity in tocilizumab-treated RA patients

    Serum calprotectin levels could represent a useful biomarker of inflammation in people with rheumatoid arthritis treated with the IL-6 receptor inhibitor tocilizumab, research suggests.

  2. 22-09-2022 | Polymyalgia rheumatica | News | Article

    SEMAPHORE: Tocilizumab reduces disease activity in steroid-dependent polymyalgia rheumatica

    The IL-6 receptor inhibitor tocilizumab may significantly reduce disease activity and the amount of prednisone needed in people with glucocorticoid-dependent active polymyalgia rheumatica, suggest results from a phase 3 trial published in JAMA .

  3. 07-11-2021 | ACR 2021 | Conference coverage | Article

    Tocilizumab candidate for glucocorticoid-sparing agent in polymyalgia rheumatica

    Tocilizumab improves glucocorticoid-free remission rates, time to first relapse, and cumulative glucocorticoid dose versus placebo in people with polymyalgia rheumatica, show phase 2/3 study data presented at the ACR Convergence 2021 virtual meeting.

  4. 25-06-2021 | COVID-19 | News | Article
    approvalsWatch

    FDA authorizes tocilizumab for severe COVID-19

    medwireNews : The US FDA has issued an Emergency Use Authorization permitting the use of tocilizumab for the treatment of some hospitalized patients with severe COVID-19.

  5. 03-06-2021 | EULAR 2021 | Conference coverage | Article

    Support for glucocorticoid-sparing effect of tocilizumab in giant cell arteritis

    Tocilizumab monotherapy following an ultra-short pulse of glucocorticoid treatment may be effective for inducing and maintaining remission in patients with new-onset giant cell arteritis, suggest preliminary study findings.

  6. 11-03-2021 | Systemic sclerosis | News | Article
    approvalsWatch

    FDA approves tocilizumab for SSc-ILD

    medwireNews : Tocilizumab has been approved by the US FDA for slowing the rate of decline in respiratory function in patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD).

  7. 23-02-2021 | Giant cell arteritis | News | Article

    Real-world data show tocilizumab effectiveness for GCA

    Real-world data confirm the effectiveness of tocilizumab for decreasing relapse risk and allowing corticosteroid reduction in heavily treated patients with giant cell arteritis.

  8. 08-03-2021 | Tocilizumab | News | Article

    COVINTOC: Routine use of tocilizumab not supported for COVID-19

    The addition of tocilizumab to standard care does not reduce the risk for disease progression among hospitalized patients with moderate-to-severe COVID-19, suggest findings from the COVINTOC trial conducted in India.

  9. 27-01-2021 | COVID-19 | News | Article
    News in brief

    Tocilizumab, sarilumab authorized for UK patients with critical COVID-19

    The IL-6 receptor inhibitors tocilizumab and sarilumab have been authorized for the off-label treatment of COVID-19 in patients admitted to intensive care units in the UK.

  10. 21-01-2021 | COVID-19 | Highlight | Teaser
    Spotlight on: Repurposing rheumatology drugs for COVID-19

    No benefit of tocilizumab for people with severe COVID-19

    Adding tocilizumab to standard care does not improve clinical outcomes for people with severe or critical COVID-19 and may increase mortality risk, according to findings from the TOCIBRAS trial published in The BMJ .

  11. 21-01-2021 | COVID-19 | News | Article

    No benefit of tocilizumab for people with severe COVID-19

    Adding tocilizumab to standard care does not improve clinical outcomes for people with severe or critical COVID-19 and may increase mortality risk, according to findings from the TOCIBRAS trial published in The BMJ .

  12. 21-12-2020 | COVID-19 | News | Article

    EMPACTA trial: Tocilizumab may improve some COVID-19 outcomes

    Adding the IL-6 receptor inhibitor tocilizumab to standard care reduces the risk for progression to mechanical ventilation or death among hospitalized patients with COVID-19 pneumonia, show findings from the EMPACTA randomized controlled trial.

  13. 21-12-2020 | COVID-19 | Highlight | Teaser
    Spotlight on: Repurposing rheumatology drugs for COVID-19

    EMPACTA trial: Tocilizumab may improve some COVID-19 outcomes

    Adding the IL-6 receptor inhibitor tocilizumab to standard care reduces the risk for progression to mechanical ventilation or death among hospitalized patients with COVID-19 pneumonia, show findings from the EMPACTA randomized controlled trial.

  14. 21-12-2020 | COVID-19 | Highlight | Teaser
    medwireNews top story

    EMPACTA trial: Tocilizumab may improve some COVID-19 outcomes

    Adding the IL-6 receptor inhibitor tocilizumab to standard care reduces the risk for progression to mechanical ventilation or death among hospitalized patients with COVID-19 pneumonia, show findings from the EMPACTA randomized controlled trial.

  15. 17-12-2020 | Rheumatoid arthritis | News | Article

    Adding methotrexate to tocilizumab not always beneficial in RA

    Combination therapy with tocilizumab and methotrexate is not always more effective than tocilizumab monotherapy for the prevention of radiographic progression in rheumatoid arthritis, study findings indicate.

  16. 30-10-2020 | Osteoarthritis | News | Article

    No improvement in hand osteoarthritis with tocilizumab

    The IL-6 inhibitor tocilizumab does not improve pain or function in patients with hand osteoarthritis relative to placebo, suggests research reported in the Annals of the Rheumatic Diseases .

  17. play
    09-11-2020 | ACR 2020 | Conference coverage | Video

    Trial suggests no benefit of tocilizumab for COVID-19

    John Stone talks about the BACC Bay Tocilizumab Trial, which demonstrated similar outcomes among hospitalized COVID-19 patients treated with the IL-6 inhibitor versus placebo in addition to standard care.

  18. 09-11-2020 | COVID-19 | Highlight | Teaser

    Trial suggests no benefit of tocilizumab for COVID-19

    John Stone talks about the BACC Bay Tocilizumab Trial, which demonstrated similar outcomes among hospitalized COVID-19 patients treated with the IL-6 inhibitor versus placebo in addition to standard care (6:47).

  19. 24-09-2020 | Juvenile idiopathic arthritis | News | Article

    Tocilizumab may delay joint damage in JIA

    The majority of patients with systemic or polyarticular-course juvenile idiopathic arthritis do not develop radiographic joint progression during the first 2 years of tocilizumab treatment, research shows.

  20. 06-11-2020 | ACR 2020 | Conference coverage | Article

    Optimizing tocilizumab dosing benefits RA patients who do not initially respond

    Escalating tocilizumab treatment from every 2 weeks to weekly could benefit patients with rheumatoid arthritis who fail to achieve low disease activity within 12 weeks, suggests research.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.